[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544618":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":18,"locations":18,"responsibleParty":19,"collaborators":18,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":25,"acronym":15,"eligibilityCriteria":26,"healthyVolunteers":23,"sex":27,"minAge":28,"maxAge":18,"enrollmentInfo":29,"targetDuration":18,"studyType":32,"phases":33,"briefSummary":35,"conditions":36,"keywords":18,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":18},{"fullName":5,"class":6},"CerbaXpert","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"pregnant women","Pregnant woman over 18 years old\n\n\\- Woman whose gestational age is less than 30 weeks",[12],"Other: Pregiferon",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Pregiferon","This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier",[9],null,{"type":20,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100544618","study-of-the-transmission-of-anti-interferon-type-1-alpha-autoantibodies-from-mother-to-child-via-the-placental-barrier-100544618",false,"NCT06371235","Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier","Inclusion Criteria:\n\n* Pregnant woman over 18 years old\n* Woman whose gestational age is less than 30 weeks.\n* Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks\n* Give birth in the inclusion center\n* Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status\n* Affiliated with the Social Security system\n\nExclusion Criteria:\n\n* Patient who underwent a blood transfusion less than 2 months ago\n* Patient who received an organ transplant\n* Patient undergoing immunotherapy, stem cell therapy and\u002For other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion","FEMALE","18 Years",{"count":30,"type":31},250,"ESTIMATED","INTERVENTIONAL",[34],"NA","The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy.",[37],"Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons","NOT_YET_RECRUITING","2024-04-12",{"date":41,"type":42},"2024-04-17","ACTUAL",{"date":44,"type":31},"2024-09",{"date":46,"type":31},"2027-03",{"name":5,"class":6}]